The estimated Net Worth of Derrick Sung is at least $4.11 Milion dollars as of 1 September 2023. Dr Sung owns over 4,219 units of Pulmonx Corp stock worth over $3,030,568 and over the last 8 years he sold LUNG stock worth over $1,077,737.
Dr has made over 22 trades of the Pulmonx Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 4,219 units of LUNG stock worth $42,190 on 1 September 2023.
The largest trade he's ever made was exercising 10,125 units of Pulmonx Corp stock on 28 January 2019 worth over $183,465. On average, Dr trades about 3,917 units every 69 days since 2017. As of 1 September 2023 he still owns at least 391,041 units of Pulmonx Corp stock.
You can see the complete history of Dr Sung stock trades at the bottom of the page.
Dr. Derrick Sung is the Chief Financial Officer at Pulmonx Corp.
Dr Sung is 48, he's been the Chief Financial Officer of Pulmonx Corp since . There are 3 older and 1 younger executives at Pulmonx Corp. The oldest executive at Pulmonx Corp is David A. Lehman, 60, who is the Gen. Counsel & Sec..
Derrick's mailing address filed with the SEC is C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063.
Over the last 4 years, insiders at Pulmonx Corp have traded over $195,808,760 worth of Pulmonx Corp stock and bought 107,681 units worth $1,883,657 . The most active insiders traders include Scientific Corp Boston, Thomas William Burns oraz Glendon E. Iii French. On average, Pulmonx Corp executives and independent directors trade stock every 13 days with the average trade being worth of $393,258. The most recent stock trade was executed by Geoffrey Beran Rose on 3 September 2024, trading 4,586 units of LUNG stock currently worth $30,726.
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corp executives and other stock owners filed with the SEC include: